AHK-Cu
← Back to LibraryCompound Profile
AHK-Cu is reviewed here for tissue repair and recovery.
Research Summary
Published literature searches and source-listed protocols
Tissue repair, Injury recovery, Gut support
Target context: Endothelial Cells
Limited or not established.
Treat protocols as educational examples unless stronger sources are listed.
Route(s)
Subcutaneous
Typical dose
1.0mg to 2.0mg
Dosing window
Anytime
Receptor / target
Endothelial Cells
Properties
Not listed
Pre-mixed
No
How AHK-Cu is studied around hair
AHK-Cu is a copper peptide discussed mainly around hair-follicle and scalp research.
Hairline — Follicle Support
Human follicle lab researchStudied for how it may support cells involved in hair growth.
Scalp — Scalp Environment
Laboratory researchStudied for follicle health and the tissue surrounding the hair root.
Hair Length — Growth Cycle
Laboratory researchStudied in laboratory research for possible effects on the hair-growth cycle.
Protocols
Standard Protocol
| Timeframe | Dose | Notes |
|---|---|---|
| Weeks 1-8 | 1.0mg to 2.0mg daily | Subcutaneous for systemic effect. |
Protocol example for research-context comparison; verify against the evidence status and listed medical sources.
Protocol logic check
Medical literature and study context
Medical-source summary: This section ties the page to medical literature, drug labels, trial registries, and regulatory sources. It is educational context only and should not be read as medical advice or a use recommendation.
| Evidence position | No approved FDA label was identified for this entry; evidence should be treated as literature context rather than validated dosing guidance. |
|---|---|
| Where studied | Studied mainly in wound, tendon, ligament, gut, inflammation, angiogenesis, and tissue-repair models; human evidence varies widely by compound. |
| Source systems checked | FDA regulatory pages; PubMed/PMC literature; ClinicalTrials.gov records; NIH ODS fact sheets |
| Target and route context | Target/receptor: Endothelial Cells. Route(s): Subcutaneous. Dosing window on page: Anytime. |
| Protocol anchor | No source-backed label or clinical-trial regimen was identified for this page; protocol examples are research-context comparisons only. |
| Main evidence limit | Key limitation: literature may be preclinical, indirect, old, region-specific, or sparse; absence of a label means no validated dosing standard. |
Source-linked findings
- Repair claims often come from animal, cell, tendon, gut, and angiogenesis models; those models can explain mechanisms but do not prove human recovery protocols.
- Rehab, diagnosis, infection control, vascular risk, anticoagulants, and malignancy history can change the safety interpretation.
- No approved-label regimen was identified for this entry. Dosing examples should be treated as unverified protocol examples.
Protocol and study notes
- No source-backed label or clinical-trial regimen was identified for this page; protocol examples are research-context comparisons only.
- On-page protocol examples summarized for comparison: Standard Protocol: Weeks 1-8, 1.0mg to 2.0mg daily.
- Key limitation: literature may be preclinical, indirect, old, region-specific, or sparse; absence of a label means no validated dosing standard.
- Monitor injury diagnosis, rehab loading, infection, anticoagulant use, abnormal vessel growth, cancer history, and injection-site sterility.
Selected medical sources
Independent evidence
Regulatory status: no approved label identified
Storage
No approved-label storage guidance was identified for this entry. Use conservative sterile handling and see the general storage guidance in the FAQ.
Contraindications & cautions
Evidence varies by item. Some points come from labels, published literature, or regulatory context; others are mechanism-based cautions that still need confirmation against medical literature. Use the medical sources below to verify details.
- Wilson's disease or other genetic copper metabolism disorders: the injectable copper complex bypasses normal hepatic copper handling; contraindicated in any subject with impaired copper transport.
- Known copper hypersensitivity or copper allergy: systemic injection may provoke significant immune/inflammatory reactions in copper-sensitive individuals.
- Active malignancy: AHK-Cu promotes endothelial cell proliferation and angiogenesis; in the context of active cancer these mechanisms could support tumor vascularization.
- Pregnancy: no human safety data; copper homeostasis is critical during fetal development.
- Breastfeeding: no established safety data.
- Known hypersensitivity to AHK-Cu or peptide excipients.
- Concurrent use of copper-chelating agents (e.g., penicillamine, trientine, high-dose zinc): will competitively neutralize the copper complex.
- Elevated baseline serum copper levels or hemochromatosis: impaired metal homeostasis increases copper toxicity risk at injectable doses.
Possible side effects
Evidence varies by item. Some points come from labels, published literature, or regulatory context; others are mechanism-based cautions that still need confirmation against medical literature. Use the medical sources below to verify details.
- Severe Post-Injection Pain (PIP) and welting: the primary and expected adverse effect of subcutaneous AHK-Cu; burning, stinging, redness, and local welt formation at the injection site; copper ion-mediated; identical in mechanism to GHK-Cu PIP; mitigated by co-injection with BPC-157 and frequent site rotation.
- Bruising and localized hematoma: common with daily administration; the 8-week cycle with rotation manages but does not eliminate this.
- Local induration and redness: tissue copper deposition response; self-resolving between injections.
- Copper toxicity at excessive doses: abdominal pain, metallic taste, nausea, vomiting, weakness, anemia; not expected at standard protocol doses but a risk with chronic accumulation.
- Transient local hyperpigmentation: tyrosinase activation from copper delivery can produce pigment changes at injection sites; typically reversible.
- Nausea: rare; copper-related at higher doses.
- Headache: uncommon.
- Mild systemic fatigue: reported in early weeks; related to angiogenic and remodeling signal activation.
Compatibility
The relationships below are heuristic compatibility notes and were not independently verified. Treat them as a starting point for a conversation with a clinician. They carry no safety guarantee.
Reported synergistic:
Reported contraindicated combinations:
None listed.